HRP20140784T1 - Glyx-13 za uporabu u postupku tretiranja refraktornih depresija - Google Patents
Glyx-13 za uporabu u postupku tretiranja refraktornih depresija Download PDFInfo
- Publication number
- HRP20140784T1 HRP20140784T1 HRP20140784AT HRP20140784T HRP20140784T1 HR P20140784 T1 HRP20140784 T1 HR P20140784T1 HR P20140784A T HRP20140784A T HR P20140784AT HR P20140784 T HRP20140784 T HR P20140784T HR P20140784 T1 HRP20140784 T1 HR P20140784T1
- Authority
- HR
- Croatia
- Prior art keywords
- glyx
- depression
- therapy
- patient
- use according
- Prior art date
Links
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 title claims 3
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 12
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000037326 chronic stress Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Glass Compositions (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Ceramic Products (AREA)
- Peptides Or Proteins (AREA)
Claims (7)
1. GLYX-13 za uporabu u postupcima tretiranja refraktorne depresije u pacijenata rezistentnih na terapiju, naznačen time da se GLYX-13 administrira navedenim pacijentima, u kojih se značajno umanjuje najmanje jedan simptom u razdoblju od 14 dana.
2. GLYX-13 za uporabu, u skladu sa zahtjevom 1, naznačen time da je depresija izabrana iz grupe koju čine velika depresija, melankolična depresija, psihotična depresija, postporođajna depresija, sezonski poremećaj raspoloženja, bipolarni poremećaj, poremećaj raspoloženja, depresija uzrokovana kroničnim medicinskim stanjem, kao što su kancer, kronična bol ili kemoterapija, kronični stres, posttraumatski stresni poremećaj i manično-depresivni poremećaj.
3. GLYX-13 za primjenu u skladu sa zahtjevima 1 ili 2, naznačeno time da se GLYX-13 administrira u količini od 0.01 mg/kg do 1000 mg/kg na dan.
4. GLYX-13 za primjenu u skladu sa bilo kojim zahtjevom 1-3, naznačen time da se GLYX-13 administrira kao i.v. doza u opsegu 1 do 10 mg/kg.
5. GLYX-13 za primjenu u skladu sa bilo kojim od zahtjeva 1 do 4, naznačeno time da se pacijent rezistentan na terapiju definira kao pacijent koji je primio terapiju najmanje dva tipa anti depresivna tretmana prije primjene GLYX-13.
6. GLYX-13 za primjenu u skladu sa zahtjevom 5, naznačeno time da je pacijent rezistentan na terapiju pacijent koji ne želi ili ne može tolerirati sporedne efekte najmanje jednog tipa antidepresivnog tretmana.
7. Primjena GLYX-13 u proizvodnji medikamenata za terapiju refraktorne depresije u terapiji rezistentnih pacijenata kojima je terapija potrebna, naznačeno time da GLYX- 13, administriran takvom pacijentu, dovodi do značajnog ublažavanja najmanje jednog simptoma tokom 14 dana.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24865009P | 2009-10-05 | 2009-10-05 | |
| PCT/US2010/051415 WO2011044089A2 (en) | 2009-10-05 | 2010-10-05 | Methods of treating depression and other related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140784T1 true HRP20140784T1 (hr) | 2014-10-10 |
Family
ID=43857351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140784AT HRP20140784T1 (hr) | 2009-10-05 | 2014-08-19 | Glyx-13 za uporabu u postupku tretiranja refraktornih depresija |
Country Status (12)
| Country | Link |
|---|---|
| EP (4) | EP2985032B1 (hr) |
| CY (1) | CY1118530T1 (hr) |
| DK (2) | DK2485751T3 (hr) |
| ES (2) | ES2493316T3 (hr) |
| HR (1) | HRP20140784T1 (hr) |
| HU (1) | HUE043807T2 (hr) |
| PL (2) | PL2985032T3 (hr) |
| PT (2) | PT2485751E (hr) |
| RS (1) | RS53513B1 (hr) |
| SI (1) | SI2485751T1 (hr) |
| SM (1) | SMT201400117B (hr) |
| WO (1) | WO2011044089A2 (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2331571B1 (en) | 2008-09-18 | 2015-08-26 | Northwestern University | Nmda receptor modulators and uses thereof |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| RU2566821C2 (ru) | 2010-02-11 | 2015-10-27 | Нортвестерн Юниверсити | Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US10583138B2 (en) | 2012-07-12 | 2020-03-10 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| SG10202010665YA (en) * | 2011-04-27 | 2020-11-27 | Univ Northwestern | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
| WO2014059326A2 (en) * | 2012-10-12 | 2014-04-17 | Northwestern University | Methods of identifying compounds for treating depression and other related diseases |
| SI2951183T1 (sl) | 2013-01-29 | 2019-07-31 | Aptinyx Inc. | Spiro-laktam NMDA receptorski modulatorji in njihove uporabe |
| KR20150110586A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| WO2014120800A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US9828384B2 (en) | 2013-01-29 | 2017-11-28 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| JP6419087B2 (ja) | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| CA2933372A1 (en) * | 2013-12-13 | 2015-06-18 | Northwestern University | Methods of treating brain disorders or identifying biomarkers related thereto |
| CN105327349A (zh) * | 2014-06-18 | 2016-02-17 | 上海翰森生物医药科技有限公司 | Nmda受体拮抗剂的医药用途及其药物组合物 |
| KR20170018072A (ko) * | 2014-06-23 | 2017-02-15 | 노오쓰웨스턴 유니버시티 | 편두통을 치료 또는 경감시키는 방법 |
| AU2015301650A1 (en) * | 2014-08-14 | 2017-03-23 | Naurex, Inc. | Methods of treating depression using NMDA modulators |
| US20180325893A1 (en) * | 2015-10-16 | 2018-11-15 | Northwestern University | Subacute administration of nmda modulators alone or in combination |
| WO2017189920A1 (en) * | 2016-04-28 | 2017-11-02 | The Trustees Of The University Of Pennsylvania | Method of drug design and optimisation utilizing stereochemical mimicry |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| JP6823083B2 (ja) | 2016-05-19 | 2021-01-27 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| CA3031563C (en) | 2016-08-01 | 2023-12-05 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| EA201990424A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые модуляторы nmda-рецептора и их применение |
| KR102465757B1 (ko) | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| PE20190502A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos |
| MX2019001318A (es) | 2016-08-01 | 2019-07-01 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos. |
| MX2020008107A (es) | 2018-01-31 | 2020-09-25 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos. |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US5763393A (en) * | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| US20030065138A1 (en) * | 2001-03-07 | 2003-04-03 | University Of Utah Research Foundation | Linear gamma-carboxyglutamate rich conotoxins |
| AU2002255705A1 (en) * | 2001-03-12 | 2002-09-24 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
| US7544478B2 (en) * | 2003-08-08 | 2009-06-09 | The Burnham Institute | Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors |
| US20050096311A1 (en) * | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
-
2010
- 2010-10-05 EP EP15171991.1A patent/EP2985032B1/en active Active
- 2010-10-05 EP EP10822514.5A patent/EP2485751B1/en active Active
- 2010-10-05 SI SI201030702T patent/SI2485751T1/sl unknown
- 2010-10-05 PT PT108225145T patent/PT2485751E/pt unknown
- 2010-10-05 ES ES10822514.5T patent/ES2493316T3/es active Active
- 2010-10-05 PT PT15171991T patent/PT2985032T/pt unknown
- 2010-10-05 PL PL15171991T patent/PL2985032T3/pl unknown
- 2010-10-05 WO PCT/US2010/051415 patent/WO2011044089A2/en active Application Filing
- 2010-10-05 EP EP18248179.6A patent/EP3488856A1/en not_active Ceased
- 2010-10-05 ES ES15171991T patent/ES2721448T3/es active Active
- 2010-10-05 PL PL10822514T patent/PL2485751T3/pl unknown
- 2010-10-05 DK DK10822514.5T patent/DK2485751T3/da active
- 2010-10-05 EP EP14169137.8A patent/EP2813236A1/en not_active Withdrawn
- 2010-10-05 RS RSP20140441 patent/RS53513B1/en unknown
- 2010-10-05 DK DK15171991.1T patent/DK2985032T3/en active
- 2010-10-05 HU HUE15171991A patent/HUE043807T2/hu unknown
-
2014
- 2014-08-13 CY CY20141100649T patent/CY1118530T1/el unknown
- 2014-08-19 HR HRP20140784AT patent/HRP20140784T1/hr unknown
- 2014-08-19 SM SM201400117T patent/SMT201400117B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2985032T3 (en) | 2019-04-15 |
| PL2485751T3 (pl) | 2014-10-31 |
| EP2985032B1 (en) | 2019-01-02 |
| DK2485751T3 (da) | 2014-08-18 |
| EP2985032A1 (en) | 2016-02-17 |
| ES2493316T3 (es) | 2014-09-11 |
| HUE043807T2 (hu) | 2019-09-30 |
| WO2011044089A2 (en) | 2011-04-14 |
| ES2721448T3 (es) | 2019-07-31 |
| SMT201400117B (it) | 2014-11-10 |
| EP3488856A1 (en) | 2019-05-29 |
| PL2985032T3 (pl) | 2019-07-31 |
| PT2985032T (pt) | 2019-04-24 |
| EP2485751B1 (en) | 2014-05-21 |
| WO2011044089A3 (en) | 2012-02-16 |
| EP2813236A1 (en) | 2014-12-17 |
| EP2485751A2 (en) | 2012-08-15 |
| CY1118530T1 (el) | 2017-07-12 |
| RS53513B1 (en) | 2015-02-27 |
| SI2485751T1 (sl) | 2014-10-30 |
| EP2485751A4 (en) | 2013-03-13 |
| PT2485751E (pt) | 2014-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140784T1 (hr) | Glyx-13 za uporabu u postupku tretiranja refraktornih depresija | |
| EA201491460A1 (ru) | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα | |
| JP2009530385A5 (ja) | うつ病の治療のためのケタミンの投与 | |
| JP2017524721A5 (hr) | ||
| WO2016172672A1 (en) | Method for treating suicidal ideation | |
| CN104127730A (zh) | 一种治疗神经衰弱的中药及其制备方法 | |
| Gosek¹ et al. | Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy | |
| CN100475249C (zh) | 一种治疗偏头痛的中药组合物 | |
| CN101596297B (zh) | 癣愈丸 | |
| HRP20120422T1 (hr) | Farmaceutski pripravak koji sadrži stefaglabrin sulfat za liječenje demijelinizirajućih bolesti živčanog sustava i za unaprjeđivanje procesa obnavljanja mijelinske ovojnice živčanih vlakana | |
| CN106177926A (zh) | 一种硬膜外滴液治疗慢性腰腿疼的药物 | |
| CN102872211B (zh) | 一种治疗鼻出血的中药及其制作方法 | |
| Kurt et al. | Comparative Efficacy of Ketamine in Treatment-Resistant Depression | |
| Marcano-Lozada et al. | MRSA Biofilm-Producer Chronic Osteomyelitis in a Diabetic Patient Successfully Treated with Antimicrobial Monotherapy | |
| CN102743496B (zh) | 一种风湿型腰腿痛用中药膏药 | |
| Koenig et al. | What are effective nonopioid medications for treating chronic neck pain? | |
| CN102078361A (zh) | 一种治疗风湿性心脏病的中药方 | |
| CN106552001A (zh) | 一种治高血压引起的头痛的配方 | |
| CN106176866A (zh) | 局部注射治疗慢性颈肩腰腿关节疼痛的药物 | |
| EA033231B1 (ru) | Способ лечения хронического полипозного риносинусита у пациентов с аспириновой триадой | |
| CN110522856A (zh) | 具有止痛功效的药物组合物 | |
| CN107970282A (zh) | 一种治疗副鼻窦炎的中药配方 | |
| CN109771607A (zh) | 一种治疗失眠多梦用的中药 | |
| CN102579853A (zh) | 一种治疗腰椎间盘突出及骨质增生的中药组合注射液配方 | |
| KR20180093599A (ko) | 애엽 추출물을 포함하는 특수 약침 |